证券日报网讯2月23日，雅本化学（300261）在互动平台回答投资者提问时表示，截至2026年2月10日， 公司股东总数为51876户。 ...

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining attention in the global health industry for its potential anti-aging benefits, DNA repair, and metabolic regulation, with significant regulatory advancements expected by 2025 [1][2]. Industry Development - The NMN industry has evolved from laboratory research to commercial applications, with major markets like the US, Japan, Canada, and Australia recognizing its legal status through various regulatory pathways [1][2]. - China is currently the largest producer of NMN raw materials, with leading companies building competitive barriers through technological innovation and industry chain layout [2][19]. NMN Definition and Function - NMN is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - As NAD+ levels decline with age, NMN supplementation can quickly elevate NAD+ levels, playing a vital role in anti-aging, cardiovascular health, and metabolic improvement [4][6]. Regulatory Environment - The global regulatory landscape for NMN is shifting from strict restrictions to cautious openness, with significant milestones achieved in various countries [17][18]. - In China, NMN has been approved as a new cosmetic ingredient and is on the path to being recognized as a health food, with the National Market Supervision Administration listing it for health food approval in April 2025 [17][18]. Market Demand - The aging population in China is expected to grow significantly, with the elderly population projected to increase from 320 million to 390 million by 2030, driving demand for anti-aging products [19]. - Younger generations are also increasingly aware of anti-aging needs, creating a dual demand for NMN products [19]. Technological Innovations - Advances in synthesis methods, particularly the full enzyme method, are driving down costs and improving product quality in the NMN industry [21][22]. - Innovations in delivery technologies are enhancing the bioavailability of NMN, ensuring better absorption and user experience [22]. Application Areas - NMN is primarily used in health supplements and cosmetics, with health supplements accounting for nearly 90% of the market share [24][28]. - Future applications are expected to expand into pet nutrition, medical health, and agricultural technology, opening new growth avenues [24][28]. Market Size and Growth - The NMN market in China is expected to exceed 3 billion yuan by 2025, driven by increasing regulatory support and expanding applications [28][32]. - The market is currently dominated by health supplements and cosmetics, with significant growth potential in other sectors as regulations ease [28][32]. Sales Channels - NMN products are primarily sold through cross-border e-commerce and private channels, with cross-border e-commerce accounting for 60%-70% of market share [35][34]. Certification and Standards - The "blue hat" certification for health foods in China represents the highest standard for NMN products, indicating safety and compliance [37]. Challenges and Opportunities - The NMN industry faces challenges such as exaggerated claims, lack of consumer awareness, and technological iterations, necessitating a focus on compliance and innovation [61][63]. - Companies are encouraged to innovate their business models and extend their value chains to enhance competitiveness [66].

Core Viewpoint - NMN (β-Nicotinamide Mononucleotide) is gaining global attention in the health industry due to its potential in anti-aging, DNA repair, and metabolic regulation, with significant advancements in regulatory approval and market potential expected by 2025 [1][2]. Group 1: NMN Definition and Function - NMN is a direct precursor to NAD+ (Nicotinamide Adenine Dinucleotide), crucial for delaying aging and enhancing physiological functions [3][4]. - Supplementing NMN can rapidly increase NAD+ levels in the body, playing a vital role in anti-aging, cardiovascular health, and cognitive function [4][6]. Group 2: Global Regulatory Landscape - By 2025, NMN's global compliance process is expected to accelerate, with major markets like the US, Japan, Canada, and Australia confirming its legal status through various regulatory pathways [1][2]. - In China, NMN has not yet received approval as a drug or health food, but it has been recognized as a new cosmetic ingredient, laying the groundwork for future regulatory developments [1][17]. Group 3: Market Demand Drivers - The aging population in China is projected to grow significantly, with the elderly population expected to increase from 320 million to 390 million between 2025 and 2030, driving the "silver economy" and demand for anti-aging products [19]. - Younger generations, particularly those born in the 1990s, are increasingly aware of anti-aging needs, creating a dual demand for NMN products [19]. Group 4: Technological Innovations - Continuous innovations in synthesis, quality testing, and delivery methods are driving the NMN industry forward, with full enzyme methods significantly enhancing production efficiency and reducing costs [21][22]. - The establishment of testing standards is raising industry entry barriers, promoting market development [22]. Group 5: Current Market Status - The NMN market in China has been expanding rapidly since its large-scale entry in 2020, with expectations to exceed 3 billion yuan by 2025 [28]. - NMN is primarily used in health supplements (approximately 90% of applications) and cosmetics (10-20%), with potential future applications in pet nutrition, medical health, and agricultural technology [24][28]. Group 6: Sales Channels - NMN products are mainly sold through cross-border e-commerce and private channels, with cross-border e-commerce accounting for 60-70% of the market share [35]. Group 7: Industry Challenges - The NMN industry faces challenges such as exaggerated claims, lack of consumer awareness, and the need for technological iteration, necessitating a focus on compliance and innovation to unlock market potential [61][63].

Core Viewpoint - Yabao Chemical announced its total external guarantee amount is RMB 137,375 million, which accounts for 68.45% of the company's latest audited net assets [2] Group 1: External Guarantees - The cumulative external guarantee amount (total amount of signed and effective guarantee agreements) is RMB 137,375 million [2] - The cumulative balance of external guarantees provided (loans secured by the company) is RMB 72,521.97 million, representing 36.14% of the company's latest audited net assets [2] - All guarantees are provided for subsidiaries within the consolidated financial statements, with no overdue guarantees or litigation-related guarantees [2] Group 2: Compliance and Risk - The company and its subsidiaries do not have any violations regarding guarantees or other guarantees for entities outside the consolidated financial statements [2]

Group 1 - The core point of the article is that Yabao Chemical reported a total of 52,205 shareholders as of January 20, 2026 [2]

Core Viewpoint - The company, Yabao Chemical, clarifies that it does not produce niacinamide and focuses on CDMO services for innovative pharmaceuticals and agricultural intermediates [1] Group 1: Business Operations - The company's NMN-related business is operating normally, organized by its overseas subsidiary and produced by compliant foreign manufacturers [1] - Products are sold through cross-border e-commerce platforms such as JD International and Pinduoduo, with product information available on these platforms [1]

Group 1 - The company, Yabao Chemical (300261.SZ), stated on the investor interaction platform that market rumors are unrelated to the company and that there are no acquisition plans [1]

Group 1 - The core viewpoint of the article is that Yabao Chemical (300261.SZ) maintains a long-term stable business partnership with Fumei, and their collaboration is currently proceeding normally [1]

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于雅本化学股份有限公司 2026 年第一次临时股东会的 法律意见书 1 3．本所及经办律师依据《证券法》《证券法律业务管理办法》《证券法律业务执 业规则》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格履行了法定 职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保证本法律意见所认 定的事实真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导 性陈述或者重大遗漏，并承担相应法律责任； 4．本法律意见书仅供贵公司本次会议之目的使用，不得用作任何其他用途。本所 律师同意将本法律意见书随贵公司本次会议决议一起予以公告。 国枫律股字[2026]A0058 号 致：雅本化学股份有限公司（"贵公司"或"雅本化学"） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见 证贵公司 2026 年第一次临时股东会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司 ...

1、本次股东会无增加、变更、否决议案的情况。 2、本次股东会以现场投票和网络投票相结合的方式召开。 一、会议召开和出席情况 雅本化学股份有限公司（以下简称"公司"）2026 年第一次临时股东会（以 下简称"股东会"）现场会议于 2026 年 2 月 12 日下午 14:30 在上海市普陀区中 江路 118 弄 22 号海亮大厦 A 座 22 层会议室召开；同时使用深圳证券交易所交 易系统网络投票于 2026 年 2 月 12 日交易时间接受网络投票，即 9:15-9:25， 9:30-11:30 和 13:00-15:00；使用深圳证券交易所互联网投票系统于 2026 年 2 月 12 日上午 9:15 至下午 15:00 期间接受网络投票。 证券代码：300261 证券简称：雅本化学 公告编号：2026-012 雅本化学股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 特别提示： 出席本次股东会的股东及股东的委托代理人共计 282 人，代表有表决权的股 份数为 270,105,512 股，占公司股份总数的 28. ...